A Trial of Sugemalimab and Chemotherapy in Unresectable Stage III NSCLC - Trial NCT05940532
Access comprehensive clinical trial information for NCT05940532 through Pure Global AI's free database. This Phase 2 trial is sponsored by Hunan Cancer Hospital and is currently Recruiting. The study focuses on Carcinoma, Non-Small-Cell Lung. Target enrollment is 41 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Hunan Cancer Hospital
Timeline & Enrollment
Phase 2
Jun 14, 2023
Dec 01, 2026
Primary Outcome
ORR
Summary
The goal of this phase II, open-label, single-arm study is to evaluate the efficacy and
 safety of induction immunotherapy and chemotherapy followed by the multidisciplinary team
 (MDT)-guided radiotherapy or surgery in unresectable, stage III non-small cell lung cancer.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05940532
Non-Device Trial